Clinical efficacy trial of PRX 106 (oral anti-TNF) for the treatment of inflammatory bowel disease.

Trial Profile

Clinical efficacy trial of PRX 106 (oral anti-TNF) for the treatment of inflammatory bowel disease.

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Etanercept (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 09 Nov 2015 According to Protalix Bio Therapeutics media release, the company anticipates commencing this trial by the first quarter of 2016,
    • 27 Jan 2015 New trial record
    • 05 Jan 2015 Results are expected in early 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top